
Will the FDA approve MDMA for PTSD?
K 13.7K contracts
1
6
Current odds
Snapshot from
As of Nov 22, 2026, 12:00 PM UTC, the highest-priced outcome on Kalshi is Before Jan 1, 2031 at 54%.
Kalshi
- Before Jan 1, 203154%
- Before Jan 1, 203053%
- Before Jan 1, 202952%
- Before Jan 1, 203251.5%
- Before Jan 1, 202842.5%
Yes prices. They are not order quotes; check each platform's rules, fees and live prices before trading.
AI Analysis
Trader mode: Market mechanics, assumptions and risks
K 13.7K contracts
Reported volume · provider units
6
Saved contracts
0
Same-question pairs
Source snapshot: Nov 22, 2026, 12:00 PM UTC
This analysis was written from an earlier market snapshot, so its prices may be older than the odds above.
Snapshot observed Nov 19, 2026, 3:00 AM UTC. This analysis describes that snapshot and is not a live news update.
What the contract measures
This Kalshi event asks whether the FDA will approve midomafetamine / MDMA for PTSD before a stated cutoff [1]. For new drugs, the excerpt counts an approval letter for a New Drug Application or Biologics License Application, and it includes standard, accelerated, and REMS-linked approvals [1]. It does not count Complete Response Letters, approvable letters, Emergency Use Authorization, or compassionate use programs [1]. Each market in this snapshot uses the same definition but a different cutoff year.
Reading the snapshot
The provider observed these prices at Nov 19, 2026, 3:00 AM UTC, and the source was retrieved at Nov 19, 2026, 3:38 AM UTC [1]. These are snapshots of listed prices, not executable quotes or verified probabilities.
Six markets are included, with cutoffs from 2027 through 2032 [1]. The Yes price is 0.09 for the 2027 cutoff and 0.425 for 2028 [1]. It rises to 0.52 for 2029, 0.53 for 2030, and 0.54 for 2031, then is 0.515 for 2032 [1]. Because each cutoff is a separate contract, these differences reflect the different time windows, and they should not be read as one forecast.
The market titles use specific years, but the rule text uses the placeholders "Jan 1, X" and "Jan 1, Y" [1]. The listed end dates fall on January 8 at 15:00 UTC for each year [1]. The excerpt also states that the listed end time is "not supplied" [1]. Readers should treat these close times as provider data, not as confirmed deadlines.
Kalshi reports a total of 13,740 contracts for this event [1]. This is provider-reported activity in contracts, not liquidity or a count of traders.
All six saved Kalshi markets for this event are included, so the sample is not partial [1]. That does not show that Kalshi lists every possible outcome.
What remains uncertain
The evidence does not explain why prices are where they are. It contains no recent news about the FDA review of this drug, and it does not show how these markets have performed historically. Whether any cutoff will be met depends on events outside this snapshot. The rules also state that the market closes early if the event occurs, and that a sponsor withdrawal before FDA action resolves to No [1]. The snapshot does not indicate whether either condition has occurred.
References
- Kalshi: Will the FDA approve MDMA for PTSD?. Provider data observed Nov 19, 2026, 3:00 AM UTC.
Snapshot observed Nov 19, 2026, 3:00 AM UTC. This analysis describes that snapshot and is not a live news update.
What the contract measures
The Kalshi event asks whether the FDA will approve midomafetamine / MDMA for PTSD before a stated deadline [1]. Qualifying approvals include standard approval, traditional approval based on clinical benefit, accelerated approval based on surrogate endpoints, and approval with a REMS or restricted indication. Complete Response Letters, approvable letters, Emergency Use Authorization, and compassionate use programs do not count [1]. If the sponsor withdraws the application before FDA action, the market resolves to No. An accelerated approval that is later withdrawn still resolves Yes if the initial approval occurred [1].
The six markets share this rule text but differ in deadline. Their titles name January 1 of each year from 2027 through 2032 [1]. The excerpt uses the placeholder "X" where a date would appear, so the year in each title is the only deadline wording supplied.
Reading the snapshot
The prices below were observed at Nov 19, 2026, 3:00 AM UTC and retrieved at 03:38:20Z [1]. They describe that moment only.
- Before Jan 1, 2027: Yes 0.09, No 0.91
- Before Jan 1, 2028: Yes 0.425, No 0.575
- Before Jan 1, 2029: Yes 0.52, No 0.48
- Before Jan 1, 2030: Yes 0.53, No 0.47
- Before Jan 1, 2031: Yes 0.54, No 0.46
- Before Jan 1, 2032: Yes 0.515, No 0.485
These are snapshot prices, not executable quotes or verified probabilities. Yes prices generally rise from 2027 to 2031, then dip slightly for 2032. The sample includes all six Kalshi markets for this event, with partialSample set to false [1]. The reported volume of 13,740 contracts uses Kalshi's own unit for this event. It should not be compared with other platforms or read as liquidity.
The provider's market end timestamps, such as Jan 8, 2027, 3:00 PM UTC, do not match the January 1 titles. The excerpt also states that the listed end time is not supplied [1]. Neither figure should be treated as confirmed closing or resolution timing.
What remains uncertain
Only Kalshi data is supplied, so no cross-platform comparison is possible. The sample warning notes that all saved markets are included, but this does not establish that the provider lists every possible real-world outcome [1]. The evidence does not explain why prices differ across deadlines or what caused any movement. It also contains no news about the application, the sponsor's status, or any scheduled FDA action. Whether the market resolves as written depends on events not covered by this snapshot.
References
- Kalshi: Will the FDA approve MDMA for PTSD?. Provider data observed Nov 19, 2026, 3:00 AM UTC.
AI-generated analysis based on market data. Not financial advice.
Saved Nov 19, 2026 UTCThis article was written from an earlier market snapshot and may be out of date. Use the dated market data and provider rules above for current information.
Overview
This contract asks whether the U.S. Food and Drug Administration (FDA) will approve midomafetamine / MDMA for post-traumatic stress disorder (PTSD) before a stated date. The contract rules use the name "midomafetamine / MDMA" [1]. MDMA itself is described in the background sources as "an entactogen with stimulant and minor psychedelic properties" [2]. A separate Wikipedia entry describes MDMA/citalopram, a combination of MDMA and the SSRI citalopram, as "under development for the treatment of post-traumatic stress disorder (PTSD)" [3]. That entry concerns the combination product, so it should not be read as describing the product named in the contract. The Kalshi contract resolves to Yes if the FDA approves the drug for marketing before the relevant January 1 deadline. The rules define an approval by type of application. For new drugs, it is the issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA). For already-marketed drugs seeking a new indication, it is approval of a supplemental application for that indication [1]. Standard approvals, accelerated approvals, approvals with a Risk Evaluation and Mitigation Strategy (REMS), and approvals with restricted distribution or indication limits all count [1]. Several outcomes do not count as approval under the rules. These include Complete Response Letters (CRLs), approvable letters that require further action, tentative approvals, requests for more information or studies, extensions of user fee dates, Emergency Use Authorizations without full approval, and approvals limited to compassionate use or export [1]. The rules also address specific scenarios. A CRL before the deadline resolves the market to No unless the FDA later approves the drug after addressing the CRL concerns and before the second deadline [1]. An approval granted after an Advisory Committee vote against approval still resolves Yes [1]. An accelerated approval that is later withdrawn still resolves Yes, because the question concerns whether the initial approval occurred [1]. If the sponsor withdraws the application before FDA action, the market resolves to No immediately, and the market closes early if the event occurs [1].
Historical Context
The supplied sources do not describe the regulatory review history of MDMA or of midomafetamine / MDMA for PTSD. They do establish that MDMA is known as ecstasy in tablet form and molly in crystal form [2], and that the MDMA/citalopram combination is described as under development for PTSD [3].
Why It Matters
The contract measures whether a specific regulatory action occurs by a stated date. It does not measure whether the drug is clinically effective, and the supplied sources do not evaluate its safety or efficacy. The prices show how the market has priced that regulatory outcome at the time of the snapshot. Each price is a snapshot, not an executable quote or a verified probability [1]. The Kalshi event contains six date-specific contracts, ranging from a Yes price of 0.09 for a deadline in 2027 to 0.54 for a deadline in 2031 [1]. The reported volume of 13,740 contracts is the total Kalshi reports for its own event. It is not a measure of liquidity or the number of traders [1]. The contract end timestamps in the saved market data are dated January 8, while the rule text refers to January 1. The supplied material does not explain this difference, so the rule text should be checked directly before relying on a deadline.
Snapshot context
The latest published provider snapshot for this topic was observed on 2026-11-19 at 03:00 UTC. It contains listings from Kalshi. Market descriptions and listed closing times define the contracts; they do not establish that the real-world outcome has occurred. This article does not include a separately verified news update. [1]
Frequently Asked Questions
Would a Complete Response Letter count as approval?
No. The rules state that Complete Response Letters indicate the application cannot be approved in its current form and do not constitute an approval [1].
Does an Emergency Use Authorization resolve the market to Yes?
The rules say an Emergency Use Authorization without full approval does not constitute an approval [1].
What happens if the sponsor withdraws the application before FDA action?
The rules say the market resolves to No immediately if the drug sponsor withdraws the application before FDA action and before the deadline, and the market closes early [1].
AI-written background. References identify the evidence used; Wikipedia links under Learn More are additional reading. Prices and provider rules are dated snapshots. This is not financial advice.
Related prediction markets
Prices are catalog snapshots and may have changed. Check each market's rules and observation time.

Will the FDA approve VERVE-102?
K 1.8K contracts
Will the FDA approve retatrutide?
PM $599.3K · K 121.2K contractsFDA approves Retatrutide this year?
Kalshi: When will the FDA approve retatrutide (LY3437943)? (Before Jan 1, 2027)
Same question, fine print differs
Related or unreviewed contracts may settle differently. Their gap is not an equivalent-contract comparison.
Saved prices; check contract rules.

When will the FDA approve Compass Pathways' COMP360 Psilocybin?
K 28.1K contracts
Will the FDA approve intismeran autogene (V940/mRNA-4157)?
K 3.2K contracts
Will the FDA approve CagriSema?
K 7.1K contracts
When will the FDA approve Intellia Therapeutics' lonvo-z?
K 6.6K contractsMarket Insights
Price gaps of 2 pp+
0
Same-question pairs
0
No outcomes on this page have been reviewed as the same question on both platforms yet.
Price differences do not establish arbitrage. Check each pair's review, current order prices, fees and settlement rules.
